CeriBell, Inc. (CBLL)
| Market Cap | 1.03B +136.3% |
| Revenue (ttm) | 108.72M +31.3% |
| Net Income | -73.88M |
| EPS | -1.95 |
| Shares Out | 38.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 436,389 |
| Open | 25.67 |
| Previous Close | 26.01 |
| Day's Range | 24.87 - 26.79 |
| 52-Week Range | 11.27 - 28.89 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 31.57 (+18.73%) |
| Earnings Date | Nov 3, 2026 |
About CBLL
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote acc... [Read more]
Financial Performance
In 2025, CeriBell's revenue was $89.06 million, an increase of 36.09% compared to the previous year's $65.44 million. Losses were -$53.41 million, 32.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price target is $31.57, which is an increase of 18.73% from the latest price.
News
Ceribell price target raised to $33 from $26 at Canaccord
Canaccord raised the firm’s price target on Ceribell (CBLL) to $33 from $26 and keeps a Buy rating on the shares. The firm updated its model following inline Q3 results…
Ceribell narrows FY26 revenue view to $115M-$117M from $114M-$117M
Consensus $114.48M. The company said, “Ceribell (CBLL) is raising its revenue guidance for the full year 2026 to a range of $115 million to $117 million, representing growth of approximately…
Ceribell reports Q3 EPS (55c), consensus (52c)
Reports Q3 revenue $29.34M, consensus $29.16M. “Our third quarter results reflect new highs in account additions and utilization within our existing account base, demonstrating the strength of our cor...
CeriBell Earnings Call Transcript: Q3 2026
Q3 revenue rose ~30% YoY on record account additions and utilization, while gross margin reached 90%. Delirium and Omni launches build toward 2027 growth, with FY2026 revenue guidance raised to $115M-$117M.
CeriBell Earnings release: Q3 2026
CeriBell released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
CeriBell Quarterly report: Q3 2026
CeriBell has published its Q3 2026 quarterly earnings report on November 3, 2026.
Ceribell Reports Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of p...
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...
Ceribell price target raised to $33 from $29 at TD Cowen
TD Cowen raised the firm’s price target on Ceribell (CBLL) to $33 from $29 and keeps a Buy rating on the shares. The firm notes that its call with the…
Ceribell receives FDA 510k clearance of quantitative EEG trending, analysis
CeriBell (CBLL) announced that the U.S. Food and Drug Administration, FDA, has cleared new software for the Ceribell System that “makes it easier and faster” for clinicians to interpret longitudinal…
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of ...
Ceribell management to meet with BTIG
Meeting to be held in New York on September 17 hosted by BTIG.
Ceribell price target raised to $30 from $28 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on Ceribell (CBLL) to $30 from $28 and keeps a Buy rating on the shares. The company has established itself as…
CeriBell Transcript: Canaccord Genuity's 46th Annual Growth Conference
Rapid EEG technology with AI is driving improved outcomes and expanding into new indications, supported by strong clinical data and favorable reimbursement. Sales force productivity and strategic account management are expected to boost growth, with new products and market segments launching over the next two years.
Ceribell price target raised to $26 from $25 at Canaccord
Canaccord raised the firm’s price target on Ceribell (CBLL) to $26 from $25 and keeps a Buy rating on the shares. The firm said Ceribell delivered another small beat &…
Ceribell reports Q2 EPS (51c), consensus (46c)
Reports Q2 revenue $28.1M, consensus $27.28M. Total revenue increased 33% year-over-year, driven primarily by continued growth in new account additions and increased utilization within existing accoun...
Ceribell raises FY26 revenue view to $114M-$117M from $112M-$116M
Consensus $114M. The updated outlook represents growth of approximately 28% to 31% over the company’s prior year revenue. This reflects continued momentum in its core business, driven by both new…
CeriBell Earnings Call Transcript: Q2 2026
Q2 2026 saw 33% revenue growth to $28.1M, record gross margins, and strong account expansion. FDA clearances, new product launches, and CMS reimbursement for Delirium monitoring set the stage for continued growth, with 2026 guidance raised and significant contributions from new products expected in 2027.
CeriBell Earnings release: Q2 2026
CeriBell released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
CeriBell Quarterly report: Q2 2026
CeriBell has published its Q2 2026 quarterly earnings report on August 10, 2026.
Ceribell announces FDA clearance for two new AI algorithm enhancements
CeriBell (CBLL) announced FDA 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact...
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of p...
CeriBell Slides: Corporate presentation
CeriBell has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.